We can help you understand the impact of Brexit on your business with our in-depth analysis and practical guides. Our macro pieces will be relevant across all sectors and help businesses understand the areas they need to consider. We also look at specific issues businesses are facing and consider the best ways to tackle them.

Broader than Brexit: Strategic Intelligence Reports

Businesses around the world are grappling with the potential impact of socio-economic and political uncertainty. This climate of uncertainty will influence their operations and the commercial and investment opportunities open to them. It is Broader than Brexit.

No-deal planning - Guidance from Hogan Lovells

The risk of no-deal Brexit is still a live one. As the political wrangling continues in Parliament our advice remains: prepare for the worst, hope for the best.

Temporary Permissions and Contract Continuity for Financial Institutions across Europe

While it is still conceivable that a deal with an appropriate transition period will be agreed between the UK and the EU, a "hard Brexit" is a real possibility.  In light of this, the UK and other jurisdictions have published legislation to accommodate the impact of a no-deal Brexit. With the assistance of our team across the jurisdictions, we have compiled information on these measures in respect of the UK, France, Germany, Luxembourg, Poland, the Netherlands, Italy and Spain.


Derogation procedures in the light of Brexit

With the anticipated departure of the United Kingdom from the EU, medical device manufacturers are exploring whether it will be possible to continue to export devices that mention a UK notified body or UK authorised representative on their label to the other EU Member States after 31 October 2019 (the scheduled date for Brexit).

The latest view: Enforcement of judgments post-Brexit in the event of a No Deal Scenario

EU Member States currently have an effective regime whereby a judgment creditor in one Member State can enforce a judgment in another Member State pursuant to Regulation (EU) No. 1215/2012 (the "Recast Brussels Regulation"). The regime under the Recast Brussels Regulation represents arguably the most comprehensive and sophisticated multilateral system of civil judicial co-operation in the world.

Snapshot of key trade law considerations arising out of Brexit

Political developments with respect to Brexit have been evolving swiftly in the past few weeks. Our International Trade team takes a look at some of the key issues if the UK leaves the EU without a deal, including the impact on customs, FTAs, export controls and sanctions plus the plan for Northern Ireland.

Brexit: Where next?

29 March Brexit is no more.  The UK Government and EU have agreed an extension to the Article 50 period until 12 April, with a further extension until 22 May if the Withdrawal Agreement is approved by the UK Parliament next week.  Our updated flowchart provides more details on the possible path ahead.

The backstop in the Withdrawal Agreement

A temporary customs arrangement to move agricultural and industrial goods across Northern Ireland, Great Britain and the EU27

A legislative storm is on its way. Is your business weather proof?

An overhaul of the UK's legal and regulatory environment of unprecedented scale and speed has begun.  The Government is whipping up a storm of secondary legislation to ready UK law for Brexit. Up to 1,000 new statutory instruments are expected in the next five months.

UK M&A: Brexit and investment in UK life sciences

While Brexit is likely to result in sweeping changes to the UK’s life sciences sector, the rate of M&A and foreign investment is a positive sign that the region will uphold its reputation as a global leader.

Braced for Brexit?

As negotiations continue, so do business preparations. Change is almost inevitable but the extent, nature and timing is uncertain. How can such change be addressed in one-off transactions (e.g. M&A) and in on-going relationships (e.g. key contracts)?

Brexit and digital health

As the UK negotiates its new relationship with the European Union, the provision of crossborder healthcare as well as the development and regulation of medical technology pose important questions.